RU2259180C2 - Method for treating ophthalmic manifestations of diseases transmitted via sexual intercourse - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: method involves administering etiotropic anti-inflammatory desensitizing and blood-vessel-strengthening preparations. 1.5% sodium deoxyribonucleate (Derinate) is additionally intramuscularly administered every other day in a course of 5 to 10 injections. The 0.25% sodium deoxyribonucleate (Derinate) is administered as single dose in to the nasal cavity and into the eye conjunctiva cavity 6 times a day.

EFFECT: enhanced effectiveness of treatment.

1 tbl

Description

The invention relates to ophthalmology and, in particular, to the treatment of ocular manifestations of sexually transmitted diseases (STDs).

There are traditional methods for treating sexually transmitted diseases (STDs): etiotropic (anti-chlamydial, anti-syphilitic, anti-anxiety, and others), anti-inflammatory, desensitizing, vasoconstrictive agents (E.S. Vakhova, Yu.F. Maychuk, 2001; S. N. Pisarenko, L.D. Lyaskovskaya // Abstract of ophthalmol. "Actual problems of inflammatory eye diseases", M., 2001, pp. 79-82, pp. 121-123). The urgency of the problem of finding new methods of treatment is associated with a significant increase in the incidence rate (3-5 times over 5 years) and the development of a protracted chronic course refractory to existing conventional therapy. The causes of the chronicity of the inflammatory process during ophthalmic manifestations of sexually transmitted diseases are the development of immunopathological reactions characterized by the imbalance of T and B cell lymphocyte populations (E.S. Vakhova, Yu.F. Maychuk. Modern algorithm for the treatment of chlamydial eye diseases // Tez conference of ophthalmologists "Actual problems of inflammatory eye diseases", M., 2001, pp. 79-82) and the presence of ophthalmoendotoxicosis (E. L. Ivanova, 2001, "Clinical significance of the study of the level of average molecules in b ial endogenous uveitis "// Proc. Conf. Ophthalmologists" Actual problems of inflammatory diseases of the eye ", M., 2001, str.51-53). In the pathogenesis of endogenous intoxication, membrane-destructive phenomena are of great importance, which largely depend on the activity of lipid peroxidation (LP).

The animal preparation Derinat (sodium deoxyribonucleate), developed by the Institute of Biophysics of the Russian Federation, significantly differing in effectiveness from all DNA-containing preparations, produced by Technomedservice, combines lymphatic drainage, immunomodulating, reparative, hemostimulating, analgesic, antiviral properties with the ability to detoxify the body and reducing the negative impact of lipid peroxidation products and various drugs (D.N. Nosik et al., 2002; T.S. Romashkina et al., 2002; G.M. Meshcheryakova, 2002; A.S. Shary in, 2002 and others // Materials of the II All-Russian conference "The use of Derinat in various fields of medicine," M., April 3-6, 2002, 64 pages). The experience of its use in ophthalmology is described for eye injuries, diabetic lesions viral and dystrophic diseases (A.D. Chuprov, O.G. Livanova, "Report on the clinical use of Derinat in ophthalmic practice" // Materials of the All-Russian Conference on the Use of Derianat, M., 2002, pp. 46-48; V.N. Kanyukov et al., "Derinat in Ophthalmic Practice", Ibid., Pp. 48-50).

Objective: improving the quality of treatment for ocular manifestations of sexually transmitted diseases using sodium deoxyribonucleate (Derinat).

The objective is achieved in that patients with a course of ocular manifestations of sexually transmitted diseases refractory to traditional therapy who have not achieved stabilization of the process are additionally prescribed Derinat intramuscularly 1.5% in 5.0 ml daily No. 5-10 injections, intranasally 0, 25% Derinat solution 6 times a day, drops in the conjunctival cavity 0.25% Derinat 6 times a day, at the same time.

Table 1.
Comparative characteristics of treatment results in patients with ocular manifestations of STDs treated with sodium deoxyribonucleate (Derinat) Patients of the experimental group treated with Derinat (55 people) Patients in the control group treated without Derinat (164 people) Duration of treatment (days) 14.05 + 0.5 *** 24.0 + 0.3 The number of complications (%) of the eyes 0 * 97 The number of relapses (%) of ocular manifestations 1.8 * 5.5 * *** - (significance of difference) p <0.001 * - p <0.05.

Example 1: Patient N. Was treated for chronic recurrent panuveitis of chlamydial etiology for 18 days without a pronounced effect by traditional means of treatment in the hospital of K., during treatment there was a decrease in vision of the right eye to 0.2, massive precipitation on the corneal endothelium, swelling of the iris, inflammatory effusion in the vitreous in the form of cellular elements and fibrin. The patient’s appointment of 1.5% Derinat to the treatment complex intramuscularly in 5.0 ml every other day No. 5, 0.25% Derinat in instillations into the conjunctival cavity 6 times a day and intranasally 6 times a day allowed to stop the inflammatory process from the eyes for 9 days, at the same time, normal blood counts were normalized (the number of leukocytes decreased from 19 to 6 thousand, ESR decreased from 40 to 15 mm / h), the immune status (the number of T and B lymphocytes increased by 35%, the number of T increased -helpers and immunoregulatory index from 1.7 to 2.5). Visual acuity was restored to 1.0, pain in the eye disappeared, precipitates and inflammatory exudate in the anterior chamber and vitreous body resolved.

Example 2: Patient K. Is annually treated in the ophthalmic department of the clinic for chronic recurrent anterior uveitis against the background of Reiter's syndrome of chlamydial etiology. Last exacerbation 6 months ago after SARS. Currently, he entered with a relapse of the disease, visual acuity = 0.1 not corr., Severe pain, pronounced phenomena of anterior uveitis. The Derinat 1.5% preparation, 5.0 ml intramuscularly every other day No. 6 and 0.25% Derinat, was administered intranasally in drops into the nostrils 6 times and into the cavity of the conjunctival sac of the left eye 6 times a day. As a result, the recovery time compared with the previous exacerbation was halved - up to 10 days. All manifestations of the disease quickly stopped and no relapse for 3 years.

Example 3: Patient S. is treated for severe panuveitis combined viral and chlamydial etiology, immunologically confirmed. Previously treated 5 years ago for 52 days. The last exacerbation arose against the background of bilateral sinusitis and eustacheitis. On admission, the visual acuity of the right eye = 0.2 not corr., Massive precipitation on the cornea, there are phenomena of vitreitis and fundus damage according to the type of juxtapaillary chorioretinitis. The patient’s treatment complex was immediately injected with 1.5% Derinatum, 5.0 ml intramuscularly every other day No. 10, 0.25% Derinatum intranasally in both nostrils 6 times a day and in the conjunctival sac of the right eye 6 times a day, which allowed stop the process within 28 days and achieve restoration of vision in less than 10 days (previously 25 days). All the phenomena of inflammation in the moisture of the anterior chamber and in the vitreous body were stopped without a trace, the patient did not need absorbable therapy (she had previously received courses of enzymes after recovery, since turbidity formed in the vitreous body).

Claims (1)

A method for the treatment of sexually transmitted diseases of the eye, consisting in the administration of etiotropic, anti-inflammatory, desensitizing and vasoconstrictive drugs, characterized in that they additionally prescribe 1.5% sodium deoxyribonucleate (Derinat) intramuscularly every other day with 5.0 ml of 5 to 10 injections, as well as simultaneously inject 0.25% sodium deoxyribonucleate (Derinat) intranasally and into the cavity of the conjunctiva of the eye 6 times a day.